Sheng-yong Yang

List of Publications by Year
in descending order

61	2,214	236612 25	233125 45
papers	citations	h-index	g-index

63	63	63	3780
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug Discovery Today, 2010, 15, 444-450.	3.2	654
2	A facile large-scale microwave synthesis of highly fluorescent carbon dots from benzenediol isomers. Journal of Materials Chemistry C, 2014, 2, 5028-5035.	2.7	80
3	Inhibition of Stat3 signaling pathway by nifuroxazide improves antitumor immunity and impairs colorectal carcinoma metastasis. Cell Death and Disease, 2018, 8, e2534-e2534.	2.7	72
4	Tet Enzymes Regulate Telomere Maintenance and Chromosomal Stability of Mouse ESCs. Cell Reports, 2016, 15, 1809-1821.	2.9	67
5	Discovery of Novel Pim-1 Kinase Inhibitors by a Hierarchical Multistage Virtual Screening Approach Based on SVM Model, Pharmacophore, and Molecular Docking. Journal of Chemical Information and Modeling, 2011, 51, 1364-1375.	2.5	66
6	NMR-filtered virtual screening leads to non-metal chelating metallo-Î²-lactamase inhibitors. Chemical Science, 2017, 8, 928-937.	3.7	63
7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)phenyl)-N8-hydroxyoct as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer. Journal of Medicinal Chemistry, 2018, 61, 3166-3192.	2.9	63
8	Structural Optimization and Structureâ€“Activity Relationships of N²-(4-(4-Methylpiperazin-1-yl)phenyl)-N⁸-phenyl-9H-purine-2,8-diamine Derivatives, a New Class of Reversible Kinase Inhibitors Targeting both EGFR-Activating and Resistance Mutations. Journal of Medicinal Chemistry, 2012, 55, 10685-10699.	2.9	50
9	Novel hybrid molecule overcomes the limited response of solid tumours to HDAC inhibitors via suppressing JAK1-STAT3-BCL2 signalling. Theranostics, 2018, 8, 4995-5011.	4.6	48
10	An integrated scheme for feature selection and parameter setting in the support vector machine modeling and its application to the prediction of pharmacokinetic properties of drugs. Artificial Intelligence in Medicine, 2009, 46, 155-163.	3.8	45
11	Discovery and structureâ€“activity relationships study of novel thieno[2,3-b]pyridine analogues as hepatitis C virus inhibitors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 1581-1588.	1.0	43
12	Design, Synthesis, and Structureâ€“Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer. Journal of Medicinal Chemistry, 2015, 58, 3957-3974.	2.9	41
13	Discovery of Imidazo[2,1-b]thiazole HCV NS4B Inhibitors Exhibiting Synergistic Effect with Other Direct-Acting Antiviral Agents. Journal of Medicinal Chemistry, 2015, 58, 2764-2778.	2.9	40
14	Discovery of Potent and Selective Inhibitors of Cdc2-Like Kinase 1 (CLK1) as a New Class of Autophagy Inducers. Journal of Medicinal Chemistry, 2017, 60, 6337-6352.	2.9	40
15	Synthesis and biological evaluation of novel (E)-Nâ€²-(2,3-dihydro-1H-inden-1-ylidene) benzohydrazides as potent LSD1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4552-4557.	1.0	34
16	Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer. European Journal of Medicinal Chemistry, 2019, 181, 111535.	2.6	34
17	Identification of 5-(2,3-Dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine Derivatives as a New Class of Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors, Which Showed Potent Activity in a Tumor Metastasis Model. Journal of Medicinal Chemistry, 2018, 61, 11398-11414.	2.9	33
18	Discovery of the Novel Potent and Selective FLT3 Inhibitor 1-{5-[7-(3-) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 72 Td (Morpholinopropoxy) Myeloid Leukemia (AML) Activities in Vitro and in Vivo. Journal of Medicinal Chemistry, 2012, 55, 3852-3866.	2.9	32

#	Article	IF	Citations
19	Structural insights into drug development strategy targeting EGFR T790M/C797S. Oncotarget, 2018, 9, 13652-13665.	0.8	31
20	SKLB-677, an FLT3 and Wnt/Î²-catenin signaling inhibitor, displays potent activity in models of FLT3-driven AML. Scientific Reports, 2015, 5, 15646.	1.6	29
21	IFPTarget: A Customized Virtual Target Identification Method Based on Proteinâ€“Ligand Interaction Fingerprinting Analyses. Journal of Chemical Information and Modeling, 2017, 57, 1640-1651.	2.5	28
22	CapsCarcino: A novel sparse data deep learning tool for predicting carcinogens. Food and Chemical Toxicology, 2020, 135, 110921.	1.8	28
23	A Preclinical Evaluation of SKLB261, a Multikinase Inhibitor of EGFR/Src/VEGFR2, as a Therapeutic Agent against Pancreatic Cancer. Molecular Cancer Therapeutics, 2015, 14, 407-418.	1.9	27
24	Drug Discovery against Psoriasis: Identification of a New Potent FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor, 1-(4-((1H-Pyrazolo[3,4-d]pyrimidin-4-yl)oxy)-3-fluorophenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea, That Showed Potent Activity in a Psoriatic Animal Model. Journal of Medicinal Chemistry, 2016, 59, 8293-8305.	2.9	27
25	Identification of new p300 histone acetyltransferase inhibitors from natural products by a customized virtual screening method. RSC Advances, 2016, 6, 61137-61140.	1.7	26
26	Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 3231-3237.	1.0	25
27	A prediction model of drug-induced ototoxicity developed by an optimal support vector machine (SVM) method. Computers in Biology and Medicine, 2014, 51, 122-127.	3.9	24
28	PRMT1 promotes neuroblastoma cell survival through ATF5. Oncogenesis, 2020, 9, 50.	2.1	24
29	LEADOPT: An automatic tool for structure-based lead optimization, and its application in structural optimizations of VEGFR2 and SYK inhibitors. European Journal of Medicinal Chemistry, 2015, 93, 523-538.	2.6	23
30	From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer. Journal of Medicinal Chemistry, 2016, 59, 9788-9805.	2.9	23
31	Discovery of selective protein arginine methyltransferase 5 inhibitors and biological evaluations. Chemical Biology and Drug Design, 2017, 89, 585-598.	1.5	22
32	Novel ROR1 inhibitor ARI-1 suppresses the development of non-small cell lung cancer. Cancer Letters, 2019, 458, 76-85.	3.2	22
33	Engineering P450 Peroxygenase to Catalyze Highly Enantioselective Epoxidation of cisâ€Î²â€Methylstyrenes. Chemistry - A European Journal, 2016, 22, 10969-10975.	1.7	21
34	Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 2016, 15, 366-378.	1.9	21
35	Improved activity of lipase immobilized in microemulsion-based organogels for (R, S)-ketoprofen ester resolution: Long-term stability and reusability. Biotechnology Reports (Amsterdam, Netherlands), 2015, 7, 1-8.	2.1	19
36	Discovery of KDM5A inhibitors: Homology modeling, virtual screening and structureâ€“activity relationship analysis. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2284-2288.	1.0	19

#	Article	IF	Citations
37	Novel dual inhibitors targeting CDK4 and VEGFR2 synergistically suppressed cancer progression and angiogenesis. European Journal of Medicinal Chemistry, 2019, 181, 111541.	2.6	19
38	Virtual screening in small molecule discovery for epigenetic targets. Methods, 2015, 71, 158-166.	1.9	18
39	Taking Quinazoline as a General Supportâ€Nog to Design Potent and Selective Kinase Inhibitors: Application to FMSâ€like Tyrosine Kinaseâ€...3. ChemMedChem, 2010, 5, 513-516.	1.6	17
40	Highly Selective, Potent, and Oral mTOR Inhibitor for Treatment of Cancer as Autophagy Inducer. Journal of Medicinal Chemistry, 2018, 61, 881-904.	2.9	17
41	Discovery of a Prenylated Flavonol Derivative as a Pin1 Inhibitor to Suppress Hepatocellular Carcinoma by Modulating MicroRNA Biogenesis. Chemistry - an Asian Journal, 2019, 14, 130-134.	1.7	17
42	Discovery and structureâ€“activity analysis of 4-((5-nitropyrimidin-4-yl)amino)benzimidamide derivatives as novel protein arginine methyltransferase 1 (PRMT1) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 5449-5453.	1.0	16
43	Discovery of pyrazolo[1,5-a]pyrimidine-3-carbonitrile derivatives as a new class of histone lysine demethylase 4D (KDM4D) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 3201-3204.	1.0	16
44	Enhanced turnover rate and enantioselectivity in the asymmetric epoxidation of styrene by new T213G mutants of CYP 119. RSC Advances, 2014, 4, 27526-27531.	1.7	15
45	<scp>TS</scp>â€Chemscore, a Targetâ€Specific Scoring Function, Significantly Improves the Performance of Scoring in Virtual Screening. Chemical Biology and Drug Design, 2015, 86, 1-8.	1.5	15
46	Discovery of 6-phenylimidazo[2,1-b]thiazole derivatives as a new type of FLT3 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 4534-4538.	1.0	13
47	Synthesis and evaluation of styrylpyran fluorophores for noninvasive detection of cerebral Î²-amyloid deposits. Bioorganic and Medicinal Chemistry, 2016, 24, 827-834.	1.4	13
48	Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants. European Journal of Medicinal Chemistry, 2018, 143, 1148-1164.	2.6	13
49	Facile Synthesis of 6-Aryl-3-cyanopyridine-2-(1H)-thiones from Aryl Ketones. Synthetic Communications, 2012, 42, 1521-1531.	1.1	11
50	A pyrane based fluorescence probe for noninvasive prediction of cerebral Î²-amyloid fibrils. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 4472-4476.	1.0	11
51	5-Methoxyquinoline Derivatives as a New Class of EZH2 Inhibitors. Molecules, 2015, 20, 7620-7636.	1.7	10
52	Discovery of 5-(4-methylpiperazin-1-yl)-2-nitroaniline derivatives as a new class of SIRT6 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127215.	1.0	10
53	DCLK1 Autoinhibition and Activation in Tumorigenesis. Innovation(China), 2021, 3, 100191.	5.2	9
54	Design, Synthesis, and Biological Evaluation of 1â€Benzylâ€1Hâ€pyrazole Derivatives as Receptor Interacting Protein 1 Kinase Inhibitors. Chemical Biology and Drug Design, 2016, 87, 569-574.	1.5	8

#	Article	IF	Citations
55	Free energy profiles for monomer capture in Grubbs- and SHOP-type olefin polymerization catalysts: A constraintab initio molecular dynamics study. Journal of Computational Chemistry, 2007, 28, 513-518.	1.5	5
56	YL4073 is a potent autophagy-stimulating antitumor agent in an in vivo model of Lewis lung carcinoma. Oncology Reports, 2016, 35, 2081-2088.	1.2	4
57	Discovery of thieno[2,3-d]pyrimidin-4(3H)-one derivatives as a new class of ROCK inhibitors. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 126966.	1.0	4
58	A novel orally available Syk/Src/Jak2 inhibitor, SKLB-850, showed potent anti-tumor activities in B cell lymphoma (BCL) models. Oncotarget, 2017, 8, 111495-111507.	0.8	3
59	Discovery of 12Oâ€”A Novel Oral Multi-Kinase Inhibitor for the Treatment of Solid Tumor. Molecules, 2020, 25, 5199.	1.7	3
60	Whether proton transition to the triphosphate tail of ATP occurs at protein kinase environment: A Carâ€Parrinello ab initio molecular dynamics study. International Journal of Quantum Chemistry, 2008, 108, 1239-1245.	1.0	1
61	Discovery of small molecule FLT3 inhibitors that are able to overcome drug-resistant mutations. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127532.	1.0	0